GSK Says Potential Blockbuster Helps Treat Common Nasal ...
5 days ago · October 14, 2024 at 3:06AM EDT. The GSK Plc headquarters in London. Photographer: Vivian Wan/Bloomberg (Vivian Wan/Bloomberg) (Bloomberg) -- GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials in a boost for the UK drugmaker’s pipeline.
GSK sues Moderna for US patent infringement over COVID, RSV ...
3 days ago · GSK seeks unspecified monetary damages from Moderna. Oct 15 (Reuters) - British drugmaker GlaxoSmithKline (GLAX.NS) sued Moderna (MRNA.O) in U.S. federal court in Delaware on Tuesday, accusing its ...
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
1 day ago · Year to date, shares of GSK have increased 5.8% against the industry’s decline of 1.8%. Image Source: Zacks Investment Research GSK's NDA Based on Data from Two Phase III Studies
Press releases - GSK
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
ViiV Healthcare shows more than 99% effectiveness in real ...
3 days ago · GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today shared the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long ...
Gepotidacin accepted for priority review by US FDA for ... - GSK
3 days ago · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for the treatment of female adults (≥40 kg) and adolescents (≥12 years, ≥40 kg) with uncomplicated urinary ...
GSK raises profit outlook on strong vaccine, HIV drug sales
May 1, 2024 · GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales growth to slow in the second half.
GSK sees strong growth as Haleon split and vaccine drive pays ...
Jan 31 (Reuters) - GSK (GSK.L) beat market estimates for fourth-quarter results on Wednesday, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs...
US FDA approves GSK’s AREXVY, the world’s first respiratory ...
May 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK set to face jury trials over heartburn drug Zantac
Jun 1, 2024 · GSK and other pharmaceutical groups are set to face jury trials in cases brought by more than 72,000 cancer sufferers who allege a heartburn drug caused their condition, after a judge in Delaware...